Elizabeth C. Hsia

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

Josef S Smolen, Jonathan Kay, Mittie K. Doyle et al. · The Lancet · 2009 · 516 citations

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +11

Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis: Twenty‐four–week results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study of golimumab before methotrexate as first‐line therapy for early‐onset rheumatoid arthritis

Paul Emery, Roy Fleischmann, Larry W. Moreland et al. · Arthritis & Rheumatism · 2009 · 393 citations · Full text

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial

Philip J. Mease, Proton Rahman, Alice B. Gottlieb et al. · The Lancet · 2020 · 325 citations · Full text

Rheumatology, Autoimmune Disease, Placebo-controlled Phase 3 +11

Three Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis

Atul Deodhar, Lianne S. Gensler, Joachim Sieper et al. · Arthritis & Rheumatology · 2018 · 311 citations · Full text

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

Atul Deodhar, Philip Helliwell, Wolf‐­Henning Boehncke et al. · The Lancet · 2020 · 307 citations

Rheumatology, Autoimmune Disease, Placebo-controlled Phase 3 +11